A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Recruiting

Phase 2

BrensocatibA Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Sponsor:

Insmed Incorporated

Code:

NCT06013241

Conditions

Chronic Rhinosinusitis Without Nasal Polyps

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Brensocatib

Placebo

Mometasone furoate nasal spray (MFNS)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by Insmed Incorporated on 2025-04-22.